Blueprint Medicines’ focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other ...

According to an international multicenter study, CD2-negative mast cells are associated with significantly reduced overall survival in patients with SM. Patients with CD2-negative mast cells have ...

Mast/stem cell growth factor receptor KIT is a receptor tyrosine kinase that plays a key role in mast cell differentiation, proliferation, survival and activation.

Mastocytosis is a group of rare haematological disorders characterised by an abnormal accumulation of clonal mast cells in the skin or other organs, particularly the bone marrow. The condition ...

What Is Advanced Systemic Mastocytosis? Mast cells, found in connective tissue throughout the body, are a type of white blood cell that helps the immune system function properly and protect against ...

-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with real-world experience observed in commercial ...

An increase of patients presenting with the complex combination of hypermobile Ehlers-Danlos syndrome (hEDS) with co-existing gastrointestinal (GI) symptoms, postural orthostatic tachycardia syndrome ...

Does it seem like the number of people you know who have sustained knee injuries has increased recently? That's likely because of a rising incidence rate in acute knee injuries, as documented and ...

Jasper Therapeutics’ monoclonal antibody briquilimab is effective at preventing mast-cell induced anaphylaxis and asthma in mice, new data suggest. In an oral presentation and two posters at the ...

CAMBRIDGE, Mass., Feb. 23, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced PIONEER trial results highlighting the long-term efficacy and safety of AYVAKIT® ...